In8bio, INC Schedule 13G passive stakes

Laurence W. Lytton and the Lytton-Kambara Foundation have jointly filed a Schedule 13G, reporting a combined 9.99% beneficial ownership in IN8BIO, Inc.

Laurence W. Lytton and Lytton-Kambara Foundation report a 9.99% passive beneficial ownership stake in IN8BIO, Inc., including common stock and warrants.

Franklin Resources, Inc. and its affiliates have reported a 9.4% beneficial ownership stake in IN8bio, Inc. common stock.

683 Capital Management, LLC and its affiliates have reported a 7.86% beneficial ownership stake in IN8BIO, Inc., including warrants.

Stonepine Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in IN8BIO, Inc., comprising common stock and prefunded warrants.

Alyeska Investment Group, L.P. and its affiliates reported a 2.58% beneficial ownership stake in IN8BIO, INC., primarily through warrants.

Transcend Partners Opportunity Fund I LLC has filed an Amendment No. 2 to its Schedule 13G, disclosing a 2.6% beneficial ownership stake in IN8BIO, INC.

William Tai-Wei Ho, an insider at IN8BIO, Inc., has disclosed a beneficial ownership of 3.7% of the company's common stock as of June 30, 2025.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.4% in IN8bio, Inc.'s common stock.

William Tai-Wei Ho has filed an amended Schedule 13G, revealing a beneficial ownership of 5.6% of IN8BIO, INC.'s common stock as of December 31, 2024.

Alyeska Investment Group, L.P. and its affiliates have reported a 9.9% beneficial ownership stake in IN8BIO, Inc. as of December 31, 2024, held for ordinary course of business.

AIGH Capital Management LLC and Orin Hirschman have disclosed a combined beneficial ownership of 8.5% of IN8bio, Inc.'s common stock as of December 31, 2024.